Drug Retail
featured
LONDON, May 14- European shares pared losses on Tuesday, with traders citing data forecasting an acceleration in U.S. chain stores sales this month. ICSC Research said it expects May same-store sales to rise between 3 and 4 percent, excluding drug store sales, in May, marking an acceleration from the 1.2 percent increase recorded in the seven days to May 11.
» Read MoreMore
-
LONDON, May 14- European shares pared losses on Tuesday, with traders citing data forecasting an acceleration in U.S. chain stores sales this month. ICSC Research said it expects May same-store sales to rise between 3 and 4 percent, excluding drug store sales, in May, marking an acceleration from the 1.2 percent increase recorded in the seven days to May 11.
-
Of the new drugs approved from 2004 through 2011, Quintiles was involved with 85 percent of the central nervous system drugs, 76 percent of oncology drugs and 72 percent of cardiovascular drugs. Mad Money host Jim Cramer explains why the stock is a buy.
-
Shares of Vivus Inc. plunged in premarket trading Wednesday after the drug developer said it absorbed a $5.8 million charge to write off unsold inventory largely from its initial production of the weight-loss drug Qsymia. Qsymia also has only been available through mail order, but Vivus said Wednesday the FDA will allow some retail pharmacy distribution.
-
May 7- The International Council of Shopping Centers and Goldman Sachs on Tuesday released the following seasonally adjusted weekly data on U.S. chain store retail sales. ICSC Research said it expects April same-store sales rose by about 3 percent excluding drug store sales.
-
**LINKEDIN CORP, Thursday close $201.67, down 9 pct premarket. **VIVUS INC, Thursday close $12.95, up 4 pct premarket.
-
*CEO still confident can keep 60 pct of business won from Walgreen fight. May 1- CVS Caremark Corp posted a higher than expected first-quarter profit on Wednesday, helped by more profitable generic drugs on the market and a severe cold and flu season that boosted sales at its drugstores.
-
Technical analyst Jeff Tomasulo is bearish on Pfizer after its big drop today. Fundamental analyst Pat Dorsey also isn't a buyer. (2:25)
-
April 30- The International Council of Shopping Centers and Goldman Sachs on Tuesday released the following seasonally adjusted weekly data on U.S. chain store retail sales. ICSC Research said it expects April same-store sales to rise between 3 and 4 percent excluding drug store sales.
-
CNBC's Andrea Day reports Swiss drug maker Novartis is disputing allegations in 2 U.S. federal lawsuits. The company is accused of wining and dining doctors.
-
NEW YORK, April 26 Fitch Ratings has affirmed its ratings on Rite Aid Corporation, including its Issuer Default Rating at' B-'. --Rite Aid's high leverage and operating statistics that significantly trail its two major competitors;.
-
April 25- Shoppers Drug Mart Corp, Canada's biggest pharmacy chain, said tightened pricing controls for generic drugs will push its 2013 pharmacy same-store sales outlook to the lower end of its previous guidance.
-
April 25- Shoppers Drug Mart Corp reported a 4 percent rise in first-quarter revenue despite tighter price controls for generics, helped by a jump in sales of over-the-counter products. Canada's biggest pharmacy chain said average prescription value fell 4.8 percent in the quarter due in part to cuts in the prices of generic drugs.
-
April 25- Shoppers Drug Mart Corp, Canada's biggest pharmacy chain, reported higher revenue, driven by an increase in sales of items such as over-the-counter drugs, cosmetics and food. Total sales in the first-quarter rose 4 percent to C $2.49 billion. Same-store sales, an important measure for retailers, rose 2.5 percent.
-
Isis Pharmaceuticals CEO Stanley Crooke discusses his new technology Antisense and its role in helping huntington's disease.
-
The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.
-
The "astonishing" growth of the middle class in emerging markets is benefiting General Mills and creating jobs in the U.S., CEO Ken Powell told CNBC's "Street Signs" on Thursday.
-
April 11- Rite Aid Corp posted its second consecutive quarterly profit on Thursday, as the third-largest U.S. drugstore chain filled more prescriptions and sold more generic drugs, which carry higher profit margins.
-
April 11- Rite Aid Corp posted its second consecutive quarterly profit on Thursday, as the third-largest U.S. drugstore chain filled more prescriptions and sold more generic drugs, which carry higher profit margins.
-
April 11- Rite Aid Corp posted its second consecutive quarterly profit on Thursday, as the third largest U.S. drugstore chain filled more prescriptions and sold more generic drugs, which carry higher profit margins.
-
Not every stock needs to have a "turbo-charged" growth angle to it. Mad Money host Jim Cramer says big pharma stocks have been red hot, and discusses which ones are worth owning.